NCT05087069View on ClinicalTrials.gov

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

April 8, 2022

Study Completion Date

January 12, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

BV100

Rifabutin for Infusion

DRUG

Placebo

Saline intravenous infusion

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors

Lead Sponsor

BioVersys SAS

Collaborators (1)

Nuvisan GmbH
All Listed Sponsors
collaborator

Nuvisan GmbH

UNKNOWN

lead

BioVersys SAS

INDUSTRY

NCT05087069 - Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter